<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/">
	<channel>
		
		<title>immunopaedia.org.za: Breaking News</title>
		<link>http://www.immunopaedia.org.za/</link>
		<description>Breaking news from immunopaedia.org.za</description>
		<language>en</language>
		<image>
			<title>immunopaedia.org.za: Breaking News</title>
			<url>http://www.immunopaedia.org.za/typo3conf/ext/tt_news/ext_icon.gif</url>
			<link>http://www.immunopaedia.org.za/</link>
			<width>18</width>
			<height>16</height>
			<description>Breaking news from immunopaedia.org.za</description>
		</image>
		<generator>TYPO3 - get.content.right</generator>
		<docs>http://blogs.law.harvard.edu/tech/rss</docs>
		
		
		
		<lastBuildDate>Wed, 19 Jun 2013 08:25:00 +0200</lastBuildDate>
		
		
		<item>
			<title>Understanding the virus-host arms race</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1523&#38;cHash=83d6ec46ee5960c1854267bb97291f18</link>
			<description>Viruses must enter cells before they can replicate, therefore they continuously evolve in order to...</description>
			<content:encoded><![CDATA[Viruses must enter cells before they can replicate,  therefore they continuously evolve in order to maintain the ability to bind to  cell-surface receptors. At the same time, host cell receptors also evolve to  counteract virus attacks. This back-and-forth evolution between virus and host  can lead to an arms race that shapes the sequences of the proteins involved.  One such example is transferrin receptor  1, which regulates iron uptake by host cells. In this study headed by Demogines  <i>et al.</i> the authors show how a small amount of mutations in transferrin  receptor 1 can alter viral host specificity. Analysis of the ratio of synonymous  to nonsynonymous DNA mutations in the rodent transferrin receptor identified a  handful of residues that were under positive selection. These residues  corresponded to the region of the receptor that interacts with the virus rather  than those residues necessary for iron uptake. A search for human  single-nucleotide polymorphisms identified transferrin receptor variants that  reduced viral uptake in cultured human cells but maintained iron regulation.  Demonstrating that in the constant arms race between viruses and the cells they  infect, positive selection of residues involved in viral entry can be divorced  from regions of the receptor that are essential for host function. Thus helping to expand our understanding of how  viruses emerge from wildlife reservoirs, and how they drive the evolution of  host genes.
<link http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001571 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Wed, 19 Jun 2013 08:25:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Immunology skills building workshop</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1522&#38;cHash=39084c527bb6c52ad3114c0cb9ab0754</link>
			<description>Immunopaedia invites you to an immunology skills building workshop taking place this week.</description>
			<content:encoded><![CDATA[Immunopaedia invites you to an immunology skills building workshop taking place this week.
Date: Thursday, 20 June 2013
Time: 16:00 – 17:30
Venue: Hall 10, ICC, Durban
This workshop takes place during the 6<sup>th</sup> South African AIDS conference, which runs from 18 - 21 June 2013 at the international conference centre (ICC)&nbsp;in Durban, South Africa. The conference provides an opportunity for participants to showcase the great work and contribution they are making in achieving our common goal of an HIV free world. If you are attending or planning to attend the conference please come and join members of the Immunopaedia team, Prof Clive Gray- chair and head of Immunology from the University of Cape Town and Shayne Loubser- PhD candidate from the AIDS Immunology Laboratory at the National Institute for Communicable Diseases in Johannesburg. The 90-minute workshop will explore the immunology of acute retroviral syndrome using materials from our award-winning online learning website. The workshop will present a clinical case study that then provides the platform for explaining the immunology of acute HIV infection, subsequent inflammation and the commencement of pathogenesis. The workshop is designed to be interactive and questions will be posed to stimulate discussions around this topic. Attendance can also earn you 2 CPD points.
We look forward to meeting you.
<link http://pag.foundation.co.za/projects/PAG/PAG.aspx>Click here to see the Conference Programme</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Tue, 18 Jun 2013 08:24:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>PrEP shown to reduce HIV in injection drug users</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1521&#38;cHash=5f27214c133bfadb9f451d028772216d</link>
			<description>A new study provides the first evidence that pre-exposure prophylaxis (PrEP) can protect...</description>
			<content:encoded><![CDATA[A new study provides the first evidence that pre-exposure prophylaxis (PrEP) can protect individuals who use injection drugs from contracting HIV. Up until now it was known that PrEP worked for all populations at increased risk for HIV, but no specific studies had been done on this population. HIV transmission amongst injection drug users (IUD) accounts for 10 percent of HIV infections worldwide and up to 80 percent in Eastern Europe and Central Asia.The research was done in collaboration with the center for disease control (CDC), the Bangkok Metropolitan Administration (BMA) and the Thailand Ministry of Public Health (MOPH). The study that was started in 2005 enrolled 2411 men and women, who were administered&nbsp; either a daily dose of tenofovir disoproxil fumarate (TDF) or a placebo. In addition participants were provided HIV prevention counseling, a risk reduction package for both sexual and drug-related risks, and monthly HIV testing.The researchers conducted two analyses. In the primary analysis, among the 1204 participants taking TDF, there were 17 HIV infections, compared with 33 infections among the 1207 participants taking placebo. This translated into a statistically significant 49 percent reduction in risk of HIV acquisition overall.&nbsp;The researchers also conducted a separate analysis to better understand the level of protection for those who adhered most closely to the daily regimen. This analysis was among participants who chose to be on directly observed therapy, met pre-established criteria for high adherence (taking TDF at least 71 percent of days and not missing more than two consecutive days) and had detectable levels of TDF in their blood. In this adherent population, HIV acquisition risk was reduced by 74 percent. Thus indicating that when used consistently and in conjunction with other proven prevention measures, PrEP can provide important additional protection for many people who remain at high risk for HIV, including IDUs. In Thailand, trial participants will now be offered access to TDF for HIV prevention for one year as part of a follow-on study that will provide additional data to help assess use and effectiveness outside of a trial setting.
<link http://www.cdc.gov/nchhstp/newsroom/2013/PrEP-Study-Press-Release.html _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Fri, 14 Jun 2013 10:01:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Blood dendritic cell frequency declines in Parkinsons Disease</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1520&#38;cHash=4e15a35a404a6b1a9e6bf0db3026fc2a</link>
			<description>Neuroinflammation is known to play an important role in the pathogenesis of Parkinsons Disease...</description>
			<content:encoded><![CDATA[Neuroinflammation is known to play an important role in the pathogenesis of Parkinsons Disease (PD), although the process is not well defined. This study therefore worked to determine whether dendritic cells (DC), a unique type of migratory immune cell that regulates immunological response and inflammation, has an impact on PD. Conducted as a case-control study, with 80 PD patients and 80 matched controls, the authors looked at the two main blood subsets of plasmacytoid and myeloid DC using flow cytometry and clinically evaluated the participants for cognitive ability, depression and motor skills using accepted PD rating scales. DC and their relationships with the clinical assessments were then evaluated. Results found that the frequency of circulating DC was decreased in patients versus matched controls (in particular the myeloid DC subset) and the number of both myeloid and plasmacytoid DC was negatively associated with motor symptom severity. Overall, the decline of blood DC, perhaps due to the recruitment of immune cells to the site of disease-specific lesions, can be considered a clue of the immune alteration that characterizes PD, suggesting innovative exploitations of DC monitoring as a clinically significant tool for PD treatment. Indeed, this study suggests that reduced peripheral blood DC are a pathologically-relevant factor of PD and also displays the urgency to better understand DC role in PD for unraveling the immune system contribution to disease progression and thus favoring the development of innovative therapies ideally based on immunomodulation.
<link http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0065352 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Thu, 13 Jun 2013 08:49:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>New four-strain influenza vaccine approved for children and adults</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1519&#38;cHash=df515e326b1e5ec8ea9d0afe93c5b377</link>
			<description>The US  Food and Drug Administration (FDA) has approved the first four-strain influenza vaccine,...</description>
			<content:encoded><![CDATA[The US &nbsp;Food and Drug Administration (FDA) has approved the first four-strain influenza vaccine, Fluzone Quadrivalent, that is approved for both adults and children starting from six months of age. The vaccine known as Fluzone Quadrivalent contains two A and two B strains, adding extra coverage to help protect against influenza disease. Epidemics of influenza B occur every two to four years in all age groups and is the strain most commonly linked to influenza-related morbidity and mortality in children and with pneumonia and other respiratory illnesses seen in adults. In recent years, up to 44 percent of influenza-associated deaths in children and adolescents 18 years of age and younger were due to influenza B. Therefore protecting against type B strains is especially important. For the past 35 years, influenza vaccines have been trivalent, providing protection against a type A(H1N1), a type A(H3N2) and only one type B strain. However, since the 2001-2002 flu season, two distinct influenza B types (the Victoria and Yamagata lineages) have co-circulated with varying prevalence, making it difficult to predict the next season’s dominant B lineage strain. In six of the past 12 seasons, the dominant circulating B strain was from the B-lineage not selected for the vaccine. Therefore this quadrivalent inactivated influenza virus vaccine will afford extra cover and protection against disease caused by the various subtypes.
<link http://www.sanofipasteur.com/articles/1244-new-four-strain-influenza-vaccine-from-sanofi-pasteur-now-licensed-by-fda-for-broad-age-range-of-children-and-adults.html _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Wed, 12 Jun 2013 13:11:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1518&#38;cHash=a1dfc79137f929807fcd76d29514458a</link>
			<description>Humoral immune responses to protein antigens are responsible for numerous unwanted medical...</description>
			<content:encoded><![CDATA[Humoral immune responses to protein antigens are responsible for numerous unwanted medical conditions such as autoimmunity and allergies, to name a few. Current treatment options largely rely on immunosuppressive drugs or immunodepletion therapy, but these approaches can compromise immunity. A more desirable approach would instead be to exploit natural mechanisms to silence or delete the antigen-reactive lymphocytes which would in turn preserves protective immunity. This study shows that liposomal nanoparticles, displaying both antigen and glycan ligands of the inhibitory coreceptor CD22, induce a tolerogenic program that selectively causes apoptosis in mouse and human B cells. These SIGLEC (sialic acid–binding Ig-like lectin) -engaging tolerance-inducing antigenic liposomes or STALs are able to induce robust antigen-specific tolerance to protein antigens in mice, preventing subsequent immune response to challenge with the same antigen. To demonstrate this concept they worked with the serious problem that affects many people with haemophilia A, that is the development of inhibitory antibodies to FVIII. Using this approach the investigators worked to see if they could induce tolerance to FVIII using a hemophilia mouse model. They found that STALs prevented formation of inhibitory FVIII antibodies, thereby allowing for effective administration of FVIII to hemophilia mice in the prevention of bleeding. In this way suggesting that STALs may provide the basis of a strategy for preventing and eliminating harmful B cell–mediated immune responses. 
<link http://www.jci.org/articles/view/69187 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Tue, 11 Jun 2013 08:45:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Visualizing cellular interactions </title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1517&#38;cHash=902147a26482b68d3c638205a3c0615e</link>
			<description>The interactions between closely aligned cells include a range of physiological processes such as...</description>
			<content:encoded><![CDATA[The interactions between closely aligned cells include a range of physiological processes such as growth, development and immune responses. However, no tools yet exist that allow the detection and visualization of these microscopic events. This study therefore reports on a strategy to visualize cell-cell interactions in live animals using bioluminescence, which occurs when lucerifase enzymes are activated by a luciferin substrate. During this process one cell population (the reporter cells) expressed luciferase, while a different cell population (the activator cells) expressed an uncaging enzyme and luciferin. The uncaging of activator cells allowed the release of luciferin, which could then diffuse into nearby reporter cells, react with luciferase, and cause the emission of light. This method provided the ability to identify and visualize metastatic sites in a mouse breast cancer model. Thus indicating that this technique works and with some further adjustments will allow for the visualization of many different cellular interactions, such as those occurring in adaptive immunity.
<link http://www.pnas.org/content/110/21/8567.abstract _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Mon, 10 Jun 2013 09:58:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Immediate-early CD8+ T Cell epitope resists CMV immunoevasion</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1516&#38;cHash=f67b4628ff6508756cbb1b2316414bdd</link>
			<description>Human cytomegalovirus (HCMV) is widespread and cannot be eliminated from the body</description>
			<content:encoded><![CDATA[Human cytomegalovirus (HCMV) is widespread and cannot be eliminated from the body. In order to maintain health the host must control the virus, which depends on CD8+ T cell responses. These responses are shaped by an individual's repertoire of MHC molecules. Virus-specific CD8-positive T cells recognize and kill infected cells before they can produce more virus. Infected cells are recognized because they display MHC class I molecules that have bound a peptide derived from a viral protein. The three most relevant human MHC I genes (HLA-A, -B, -C) occur in many allelic variants that present different viral peptides to different T cells. HCMV encodes several molecules that interfere with stability or localization of HLA class I, but it is unknown how this affects recognition by T cells that recognize infection through different HLA molecules.&nbsp;This study was able to show that HCMV immunoevasins differentially impaired T cell recognition of epitopes from the same viral antigen, known as immediate-early 1 (IE-1), that were presented by different MHC class I allotypes. They found that in the presence of immunoevasins, HLA-A- and HLA-B-restricted T cell clones were ineffective, but HLA-C*0702-restricted T cell clones recognized and killed infected cells with high efficiency. Showing that this population of HLA-C-restricted T cells has superior antiviral function and therefore may be suitable for HCMV-specific immunotherapy.
<link http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1003383 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Fri, 07 Jun 2013 08:51:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Mortality in well controlled HIV compared with mortality in the general population </title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1515&#38;cHash=6e754ef63ae857c00a97091e634ac71c</link>
			<description>With antiretroviral therapy (ART) becoming more successful, outcomes in patients with HIV have...</description>
			<content:encoded><![CDATA[With antiretroviral therapy (ART) becoming more successful, outcomes in patients with HIV have improved significantly. Data from cohort studies even suggest that people doing well on treatment, i.e. an undetectable viral load and a CD4 cell count above 500 cells/mm3, have the same life expectancies as HIV-negative individuals. To further explore this notion investigators looked at data obtained from participants enrolled in two randomized controlled trials- the SMART study (CD4 cell-guided treatment interruptions) and ESPRIT trial (HIV therapy with or without IL-2). They included 3280 participants from both trials who were non-intravenous drug users, aged 20–70 years and taking continuous antiretroviral therapy (ART). Results showed that the commonest cause of death was cardiovascular disease (CVD) or sudden death (19, 31%), followed by non-AIDS malignancy (12, 19%). Only two deaths were AIDS-related. They also found that mortality rate was increased compared with the general population with a CD4<sup>+</sup> cell count between 350 and 499cells/ul while no increase in mortality was seen with CD4<sup>+</sup> cell counts greater than 500cells/ul. Thereby concluding that if administered early enough in the treatment of HIV, modern ART Is able to reduce mortality risk to that of a normal life expectancy
<link http://journals.lww.com/aidsonline/Abstract/2013/03270/Mortality_in_well_controlled_HIV_in_the_continuous.14.aspx _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Thu, 06 Jun 2013 08:54:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>PD-L1 blockade combined with IL-2 therapy re-energise exhausted T cells</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1514&#38;cHash=69cd7a28756d1ba0afd121bb8fe38824</link>
			<description>CD8 T cells play a key role in eliminating intracellular infections and tumors. </description>
			<content:encoded><![CDATA[CD8 T cells play a key role in eliminating intracellular infections and tumors. However, in the setting of chronic antigen stimulation such as during chronic infections, CD8 T cells undergo exhaustion. Which is characterized by loss of function including impaired cytokine secretion and reduced cytotoxic killing abilities. One of the major players in this process is the inhibitory receptor programmed cell death 1 (PD-1) which is upregulated during chronic antigen stimulation and is associated with disease progression and immune dysfunction. Recent clinical trials have shown that PD-1 blockade, by in vivo administration of humanized anti–PD-1 or anti–PD-1 ligand 1 antibodies, is an effective immunotherapeutic for increasing tumor clearance by restoring T cell function. Another important cytokine is IL-2, that has a pleiotropic effect on multiple immune cell types and has been used as a therapy to augment T cell responses against virus or tumor antigens, with variable success. Therefore, in this study, the authors explored the idea of combining the positive signal of IL-2 along with the blockade of PD-1, as a therapy for chronic infection. Using the mouse lymphocytic choriomeningitis virus (LCMV) model of chronic infection, they determined the effect of daily low-dose IL-2 treatment given alone, or as a combined immunotherapy in conjunction with PD-1 blockade, on exhausted virus-specific CD8 T cells, Tregs, and viral control. The results showed that low-dose IL-2 administration alone enhanced CD8+ T cell responses in chronically infected mice. IL-2 treatment also decreased inhibitory receptor levels on virus-specific CD8+ T cells and increased expression of CD127 and CD44, resulting in a phenotype resembling that of memory T cells. An unexpected finding was that IL-2 therapy had only a minimal effect on reducing viral load. However, combining IL-2 treatment with blockade of the PD-1 inhibitory pathway had striking synergistic effects in enhancing virus-specific CD8+ T cell responses and decreasing viral load. Thus suggesting that combined IL-2 therapy and PD-L1 blockade merits consideration as a regimen for treating chronic infections and cancer.
<link http://www.jci.org/articles/view/67008 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Wed, 05 Jun 2013 09:41:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Biodegradable core–shell carriers for simultaneous encapsulation of synergistic actives</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1513&#38;cHash=547c929323f9e295b09e6bf1ddb898b7</link>
			<description>A recent publication in the Journal of the American Chemical society demonstrates a novel method...</description>
			<content:encoded><![CDATA[A recent publication in the Journal of the American Chemical society demonstrates a novel method for delivering medications simultaneously. This is an important finding because the effective treatment of many diseases, especially cancer and AIDS, requires the synergistic interaction of several drugs. However, traditional carrier systems often lack efficient encapsulation and release of incorporated substances, particularly when combinations of drugs must be released in concentrations of a prescribed ratio. To overcome this problem the authors used a microfluidic platform to create core-shell particles in which a hydrophobic drug formed the shell and a hydrophilic drug was carried in the core. In this study they used the two chemo therapeutic agents paclitaxel and doxorubicin hydrochloride. The particles, which had an overall diameter of less than 100 µm, were made with two glass capillaries drawn to fine tips inside a microfluidic channel. The finer capillary held an aqueous solution of the core drug on the inside, and the fluid outside this capillary carried the shell drug dissolved in a food-grade lipid. The drug loaded particles were then dried and stored as powders. Following this preparation the viability of the drugs were confirmed in successful testing on immortalized human cervical cancer cell lines. Showing that this solvent-free platform technology has a high potential value for delivering accurate drug combinations and increasing treatment success. 
<link http://pubs.acs.org/doi/abs/10.1021/ja401422r _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Tue, 04 Jun 2013 10:42:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Mature HIV-1 capsid structure revealed by cryo-electron microscopy</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1512&#38;cHash=191a1e39485976187b9728e2aeb47acb</link>
			<description>A team led by researchers from the University of Pittsburgh School of Medicine has for the first...</description>
			<content:encoded><![CDATA[A team led by researchers from the University of Pittsburgh School of Medicine has for the first time described the structure of the HIV capsid or protein shell. The capsid is critically important for HIV replication, therefore understanding its structure in detail, and how it separates to release its contents could reveal targets for new drugs. Previous research has shown that the cone-shaped shell is composed of identical capsid proteins linked together in a complex lattice of about 200 hexamers and 12 pentamers. But the shell is non-uniform and asymmetrical and standard structural biological methods have so far been insufficient for deciphering the molecular architecture. Therefore the team used a hybrid approach, taking data from cryo-electron microscopy at an 8-angstrom resolution to uncover how the protein hexamers&nbsp; and pentamers are connected, and cryo-electron tomography of native HIV-1 cores, isolated from virions, to join the pieces of the puzzle. They then used a supercomputer to run simulations involving 1 quadrillion operations per second, that positioned over 1300 proteins into a whole that reflected the capsid's known physical and structural characteristics. In this way the process revealed a three-helix bundle with critical molecular interactions at the seams of the capsid, areas that are necessary for the shell's assembly and stability, thus also representing vulnerabilities in the protective coat of the viral genome. Disruption at these interfaces could interfere with capsid function therefore developing drugs that prevent capsid assembly could stop the virus from reproducing.
<link http://www.nature.com/nature/journal/v497/n7451/full/nature12162.html _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Mon, 03 Jun 2013 09:10:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Depleting tumor-specific Tregs at a single site eradicates disseminated tumors</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1511&#38;cHash=d7f21420a0b209577a8a64969904f9bd</link>
			<description>Stimulation of antigen-presenting cells by Toll like receptor 9 (TLR9) agonists enhances the uptake...</description>
			<content:encoded><![CDATA[Stimulation of antigen-presenting cells by Toll like receptor 9 (TLR9) agonists enhances the uptake and presentation of antigens to the immune system. Injections of CpG oligonucleotide, a TLR9 agonist, directly into tumors, can trigger an antitumor immune response. However, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. Tregs, a subset of lymphocytes, play a central role in maintaining immunologic tolerance to normal tissues. They exert their immunosuppressive effects both by direct interaction with cells through expression of surface molecules such as CTLA-4 and by secretion of cytokines (IL-10, TGF-beta). In tumor-bearing mice, this study found that Tregs within the tumor preferentially expressed the cell surface markers CTLA-4 and OX40, and were able to&nbsp; show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. Thus demonstrating that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. 
<link http://www.jci.org/articles/view/64859 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Fri, 31 May 2013 11:36:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>HPV evades keratinocytes innate immune response </title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1510&#38;cHash=6af31c073ce694d12360e9e15ac6d8f3</link>
			<description>Chronic ongoing infection of basal keratinocytes with high-risk human papillomavirus (hrHPV) may...</description>
			<content:encoded><![CDATA[Chronic ongoing infection of basal keratinocytes with high-risk human papillomavirus (hrHPV) may cause cancer. This could be because although keratinocytes have a large array of pattern recognition receptors (PRRs) to recognize invading pathogens and activate the immune system, hrHPV has developed ways to evade the host's immune response, causing minimal inflammation, for sustained periods of time. To better understand the mechanisms underlying hrHPV's capacity to evade immunity, this study looked at PRR signaling in non, newly, and persistently hrHPV-infected keratinocytes. And found that active infection with hrHPV hampered the relay of signals downstream of the PRRs to the nucleus, thereby affecting the production of type-I interferon and pro-inflammatory cytokines and chemokines. This suppression was shown to depend on hrHPV-induced expression of the cellular protein ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in keratinocytes. Showing that UCHL1 is one of mechanisms responsible for lowering the attraction of immune cells and the chance of hrHPV-infected cells being recognized and eliminated, thus enabling hrHPV to persist.
<link http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1003384;jsessionid=26DB92BA2854A8FEE3E70C864D02923F _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Thu, 30 May 2013 09:33:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Structure and functional mechanism of a human antimicrobial membrane channel</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1509&#38;cHash=ef202f92f6718b896f71153605b772f4</link>
			<description>Multicellular organisms fight bacterial and fungal infections by producing peptide-derived...</description>
			<content:encoded><![CDATA[Multicellular organisms fight bacterial and fungal infections by producing peptide-derived broad-spectrum antibiotics. These host defense peptides compromise the integrity of microbial cell membranes and thus evade pathways by which bacteria develop rapid antibiotic resistance. In this way antimicrobial peptides (AMPs) provide an important first-line defense against bacterial and fungal infections.To better understand these mechanisms Song et al. used a combination of x-ray crystallography, electrophysiology, and molecular dynamics simulations to better understand the mechanism of one such AMP, dermicidin (DCD). DCD is secreted into human sweat and found on the skin. It is active against a range of bacteria, including methicillin-resistant Staphylococcus aureus&nbsp; (MRSA) and Mycobacterium tuberculosis (MTB). What was found was that DCD forms an architecture of high-conductance transmembrane channels, strengthened by zinc, to form hexameric barrel-like channels in bacterial membranes. The channels are highly permeable to water and ions and thereby disrupt membranes. This ability to disrupt the transmembrane potential of bacterial cell membranes can lead to rapid cell death and thus provide protective antimicrobial activity to the host.
<link http://www.pnas.org/content/early/2013/02/19/1214739110.full.pdf _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Wed, 29 May 2013 08:43:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>AZT shown to impair immunological recovery in first-line ART</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1508&#38;cHash=be270ff0e4bc73e7668233c60be2066d</link>
			<description>According to the WHO guidelines for first-line antiretroviral therapy (ART) in resource-limited...</description>
			<content:encoded><![CDATA[According to the WHO guidelines for first-line antiretroviral therapy (ART) in resource-limited settings should include nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbones of AZT and 3TC or tenofovir and 3TC. It is well known that AZT is associated with an increased risk of a range of long-term side-effects, especially anaemia. Some studies have also shown that people treated with AZT have smaller increases in CD4 cell count compared to individuals taking alternative NRTIs. However, these studies were small and had short duration of follow-up. Therefore investigators analysed immunological outcomes in over 72 000 people starting first-line ART in southern Africa. They compared immunological restoration one and five years after the initiation of treatment between individuals treated with AZT and those taking an alternative NRTI. Results found that after one and five years of therapy, participants on AZT had estimated CD4 cell counts of 301 cells/mm3 and 386 cells/mm3, while those not taking AZT had counts of 317 cells/mm3 and 442 cells/mm3 respectively. The difference between the two treatment groups was most pronounced for participants who started therapy when their CD4 cell count was below 100 cells/mm3. This is most likely related to bone marrow suppression caused by AZT. Thus concluding that initially replacing AZT with another NRTI could avoid unnecessary switches to second-line ART.
<link http://journals.lww.com/aidsonline/Abstract/publishahead/AZT_impairs_immunological_recovery_on_first_line.98593.aspx _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Tue, 28 May 2013 09:01:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Cochlin produced by follicular dendritic cells promotes antibacterial innate immunity</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1507&#38;cHash=1e481be69971112acd795ae7fb6be39f</link>
			<description>Cochlin is an extracellular matrix protein produced by follicular dendritic cells (FDCs). </description>
			<content:encoded><![CDATA[Cochlin is an extracellular matrix protein produced by follicular dendritic cells (FDCs). FDCs are known as critical modulators of humoral immunity promoting activation and maturation of B cells within follicles. The physiological function of cochlin, however, is unknown. This study therefore worked to better understand this protein and shows that cochlin is specifically expressed by follicular dendritic cells and selectively localized in the fine extracellular network of conduits in the spleen and lymph nodes. During inflammation, cochlin was shown to be secreted into blood circulation. In models of lung infection with Pseudomonas aeruginosa and Staphylococcus aureus, Coch<sup>-/-</sup> mice showed reduced survival linked to defects in local cytokine production, recruitment of immune effector cells, and bacterial clearance. Thus demonstrating an unexpected function of FDC in modulating innate immunity and a role for secondary lymphoid organ and particularly local lymph nodes in the amplification of the innate immune response by the release of modulators such as cochlin. 
<link http://www.cell.com/immunity/abstract/S1074-7613(13)00197-0? - external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Mon, 27 May 2013 09:53:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Elimination of self-reactive T Cells in the thymus: A timeline for negative selection</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1506&#38;cHash=5e06c60e144d321efff4250bf0f54172</link>
			<description>T cells bearing autoreactive T cell antigen receptors are typically eliminated via thymocyte...</description>
			<content:encoded><![CDATA[T cells bearing autoreactive T cell antigen receptors are typically eliminated via thymocyte apoptosis and removed by thymic phagocytes during development in the thymus, in order to protect against autoimmunity. This process is known as negative selection. However, the sequence of events that occur <i>in vivo</i>, and the relationship between thymocyte death and phagocytic clearance, are unknown. This study therefore examined a synchronized population of developing thymocyte undergoing negative selection within three-dimensional living thymic tissue. However in spite of this synchronized early response, individual thymocytes then undergo a delayed and asynchronous entry into apoptosis somewhere between 2 and 12 hours later. Using time-lapse two-photon imaging, the study then showed that thymocyte death and the clearance of the dead cells actually occurs at the same time, with thymocytes already engulfed by a macrophage before the cell death-related changes in chromatin and membrane permeability are evident. Thus providing a timeline of the major events during negative selection, and suggesting close coupling between thymocyte death and clearance by macrophages.
<link http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001566;jsessionid=8D21C6716E9B5AF8B5C950F57F15A975 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Fri, 24 May 2013 08:42:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Dupilumab in persistent asthma with elevated eosinophils</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1505&#38;cHash=6dd7d7b547779b4a0a9c55515b27c549</link>
			<description>This week drug makers Sanofi and Regeneron announced results from their Phase 2a study of the...</description>
			<content:encoded><![CDATA[This week drug makers Sanofi and Regeneron announced results from their Phase 2a study of the asthma drug Dupilumab, for the treatment of patients with moderate-to-severe allergic asthma. Dupilumab is an investigational monoclonal antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), which modulates signaling of both IL-4 and IL-13, drivers of Th2 (Type 2 helper T cell) immune response. &nbsp;The proof-of-concept study enrolled 104 patients with moderate-to-severe, persistent asthma that was not well controlled with inhaled glucocorticosteroids (ICS) and long-acting beta agonist (LABA) therapy, and who had elevated eosinophils in blood or sputum. The primary objective of the trial was to assess the effect of dupilumab, dosed subcutaneously, once a week for twelve weeks. Study participants were divided into treatment and placebo groups of 52 in each group. All patients received ICS and LABA, with the treatment group receiving dupilumab and the placebo group given subcutaneous placebo.&nbsp; The LABA was withdrawn at week four and the ICS was tapered to withdrawal between weeks six and nine.&nbsp; Patients were treated for 12 weeks or until they experienced a protocol-defined asthma exacerbation, the primary endpoint of the study. &nbsp;Results found that 23 patients (44.2%) receiving placebo experienced an asthma exacerbation compared to three patients (5.8%) receiving dupilumab, resulting in an 87% reduction in the incidence of asthma exacerbations for the dupilumab arm. Clinically meaningful and statistically significant improvements were also observed for lung function and forced expiratory volume over one second (FEV1). Adverse events were generally non-specific and of mild-to-moderate intensity. &nbsp;In conclusion the study indicated a potential role for IL-4/IL-13 blockade in a subpopulation of patients with persistent asthma. However the study was only for 12 weeks, indicating the need for longer studies to confirm these observations. 
<link http://www.nejm.org/doi/full/10.1056/NEJMoa1304048?query=featured_home#t=article _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Thu, 23 May 2013 09:01:00 +0200</pubDate>
			
		</item>
		
		<item>
			<title>Discovering naturally processed antigenic determinants that confer protective T cell immunity</title>
			<link>http://www.immunopaedia.org.za/index.php?id=235&#38;L=0%20and%201%3D1--&#38;tx_ttnews%5Btt_news%5D=1504&#38;cHash=058b13d9a22e1bbed88f1443d0beb74a</link>
			<description>Understanding vaccine-mediated correlates of immunity is critical for the design of novel...</description>
			<content:encoded><![CDATA[Understanding vaccine-mediated correlates of immunity is critical for the design of novel pathogen-free vaccines against diseases caused by complex pathogens such as HIV, malaria and TB. CD8+ T cells (TCD8) confer protective immunity against these infectious diseases, thereby suggesting that microbial TCD8 determinants are promising vaccine targets. However current T cell antigen identification approaches do not discern which epitopes drive protective immunity during active infection, key information for the rational design of TCD8-targeted vaccines. This study therefore used a proteomics-based approach for large-scale discovery of naturally processed determinants derived from a complex pathogen, vaccinia virus (VACV). VACV consists of about 200 proteins making it an ideal model for studying TCD8 responses to pathogens with complex proteomes. Immunologic characterization revealed that many previously unidentified VACV determinants were recognized by smallpox-vaccinated human peripheral blood cells in a partially overlapping or variegated manner. Many of these determinants were also recognized by HLA class I–transgenic mouse immune TCD8, which were then able to elicit protective TCD8 immunity against lethal intranasal VACV infection. Of note, efficient processing and stable presentation of immune determinants as well as the availability of naive TCD8 precursors were sufficient to drive a multifunctional, protective TCD8 response. Therefore showing that this strategy in which fundamental insights into T cell epitope processing and presentation were used to define targets of protective TCD8 immunity may provide general application for future vaccine research. 
<link http://www.jci.org/articles/view/67388 _blank external-link-new-window "Opens external link in new window">Link to article</link>]]></content:encoded>
			<category>Breaking News</category>
			
			
			<pubDate>Wed, 22 May 2013 08:53:00 +0200</pubDate>
			
		</item>
		
	</channel>
</rss>